Allergic Inflammation Is Associated With Coronary Instability and a Worse Clinical Outcome After Acute Myocardial Infarction
Authors:
- Giampaolo NiccoliGNGiampaolo Niccoli
- Camilla CalvieriCCCamilla Calvieri
- Davide FlegoDFDavide Flego
- Giancarla ScaloneGSGiancarla Scalone
- Asya ImaevaAIAsya Imaeva
- Vito SabatoVSVito Sabato
- Domenico SchiavinoDSDomenico Schiavino
- Giovanna LiuzzoGLGiovanna Liuzzo
- Filippo CreaFCFilippo Crea
- 1 August 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 8 (8) , e002554
Abstract
Background—: The role of allergic inflammation in acute coronary syndromes (ACS) has not been clearly defined to date. Aim of this study was to assess eosinophil and basophil activation in ACS and the prognostic role of eosinophil cationic protein in ST-segment–elevation myocardial infarction. Methods and Results—: In a cross-sectional study, we prospectively enrolled 51 patients undergoing percutaneous coronary intervention (60.8% patients with ACS and 39.2% with stable angina). Flow cytometry analysis assessed CD66b, CD69, and CD203c median fluorescence intensity expression. In a follow-up study, 181 patients presenting with ST-segment–elevation myocardial infarction, undergoing primary percutaneous coronary intervention, were prospectively enrolled with a follow-up of 24 months. Eosinophil activation (CD66b) was similar in patients with ACS and stable angina (6.61 [4.91–7.72] versus 6.62 [5.27–8.73], P =0.63), whereas eosinophil degranulation (CD69) and basophil activation (CD203c) were higher in ACS patients compared with stable angina patients (1.38 [1.16–1.52] versus 1.17 [1–1.31], P =0.01); 0.97 [0.89–1.11] versus 0.92 [0.87–0.95], P =0.03, respectively). Eosinophil cationic protein serum levels were significantly higher in ST-segment–elevation myocardial infarction patients with major adverse cardiac events as compared with those without (21.1 [10.37–25.65] versus 7.83 [3.37–12.8] μg/L, P =0.01) and in patients with thrombus score >3 compared with those with thrombus score ≤3 (15.0 [9.8–24.7] versus 5.2 [3.5–22.9] μg/L, P =0.006). Eosinophil cationic protein serum levels predicted major adverse cardiac events during follow-up (odds ratio =1.041, 95% confidence interval 1.012–1.071, P =0.005). C-reactive protein serum levels showed a borderline statistical significance (odds ratio =0.904, 95% confidence interval 0.806–1.014, P =0.085). Conclusions—: These findings are the first demonstration of in vivo eosinophil degranulation and basophil activation during ACS and of the prognostic role of eosinophil cationic protein in ST-segment–elevation myocardial infarction.Keywords
This publication has 29 references indexed in Scilit:
- Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknownEuropean Heart Journal, 2012
- Eosinophil cationic protein and clinical outcome after bare metal stent implantationAtherosclerosis, 2010
- Eosinophil cationic protein: A new biomarker of coronary atherosclerosisAtherosclerosis, 2010
- Fluvastatin and lovastatin inhibit granulocyte macrophage–colony stimulating factor‐stimulated human eosinophil adhesion to inter‐cellular adhesion molecule‐1 under flow conditionsClinical & Experimental Allergy, 2009
- Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent ThrombosisCirculation, 2009
- Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stentsEuropean Heart Journal, 2009
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsJournal of Allergy and Clinical Immunology, 2008
- The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory statesBlood, 2006
- Lessons From Sudden Coronary DeathArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- CD69 is expressed on platelets and mediates platelet activation and aggregation.Journal of Experimental Medicine, 1990